Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
暂无分享,去创建一个
M. Lebwohl | L. Puig | H. Bachelez | J. Sobell | A. Jacobson
[1] S. Ball,et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three‐year results from the UNCOVER‐3 study , 2018, Journal of the American Academy of Dermatology.
[2] A. Kimball,et al. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. , 2018, Journal of drugs in dermatology : JDD.
[3] M. Lebwohl,et al. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials , 2018, Journal of the American Academy of Dermatology.
[4] L. Iversen,et al. Efficacy and safety of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER‐3) , 2017, Journal of the American Academy of Dermatology.
[5] T. Luger,et al. Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study , 2017, The British journal of dermatology.
[6] K. Reich,et al. Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results. , 2017, Journal of Drugs in Dermatology.
[7] A. Kimball,et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials , 2017, The Lancet.
[8] A. Gottlieb,et al. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis , 2016, The British journal of dermatology.
[9] B. Strober,et al. Clinical meaningfulness of complete skin clearance in psoriasis. , 2016, Journal of the American Academy of Dermatology.
[10] H. Nakagawa,et al. Long‐term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate‐to‐severe plaque psoriasis , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.
[11] H. Nakagawa,et al. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. , 2016, Journal of dermatological science.
[12] B. Strober,et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. , 2015, The New England journal of medicine.
[13] J. Koo,et al. Biologic fatigue in psoriasis , 2014, The Journal of dermatological treatment.
[14] A. Kimball,et al. Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[15] B. Strober,et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. , 2012, Journal of the American Academy of Dermatology.
[16] A. Kimball,et al. Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial through up to 3 years , 2012, The British journal of dermatology.